Abstract 4479
Background
Gemcitabine with platinum is regarded as the standard of care in patients with unresectable and/or metastatic disease with good performance status (PS). There is no standard of care for poor PS patients. A report from M.D.A.C.C. stated a median OS of only one month in GBC patients with poor PS. Erlotinib and capecitabine, both have shown efficacy in metastatic GBC. There has been no RCT to date in GBC patients with poor PS. With limited data showing the activity of erlotinib and capecitabine, we conducted this RCT to evaluate the efficacy and toxicity of these drugs in this patient cohort.
Methods
This is an ongoing open-label, phase II/III RCT (phase II part of the study is complete).The primary objective is to determine if erlotinib (150 mg/d PO )+ BSC or capecitabine (625 mg/m2 BD PO) + BSC has an OS benefit compared to BSC alone in patients with unresectable/metastatic GBC with ECOG PS III. A total of 51 patients with histopathologically confirmed GBC, age >/=18 years, with adequate organ functions (S. bilirubin < = 3.5 g/dl, AST/ALT within 5 times the normal limit and eGFR > 50 ml/min/1.73m2) were randomised. Patients were followed up q2wk in first month and q4wk thereafter. Toxicity was assessed using CTCAE v4.1. Radiological response evaluation (as per RECIST v1.1) was done at 8-10 weeks/earlier if clinically indicated, QoL assessment (using EORTC QLQ-C30 BIL21 ) was done at baseline and at 6-8 weeks. Intervention was continued until progression/unacceptable toxicity. Serial evaluation for OS in all three arms was done. Initially the study was started as a phase II RCT, an interim pre-planned analysis was done after completion of phase II.
Results
The median OS in capecitabine +BSC arm (n = 19) was 209 days, relotinib +BSC arm(n = 14) was 105 days and BSC alone arm was 71 days (p value 0.022). Only 2 patients had grade III diarrhea with erlotinib. There were no drug-related SAEs.
Conclusions
There is a statistically significant OS benefit of capecitabine+BSC or erlotinib+BSC over BSC alone in unresectable/metastatic GBC patients with ECOG PS III. Results will be updated upon completion of phase III.
Clinical trial identification
CTRI/2019/04/018860.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
All India Institute of Academic Sciences.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4732 - Progesterone Receptor Isoform Ratio Dictates Antiprogestins/Progestins Effects on Metastatic Breast Cancer Models
Presenter: Maria Abascal
Session: Poster Display session 2
Resources:
Abstract
5737 - PAM50 and CGH-array genomic characterization of HER2-Equivocal Breast Cancers defined by the 2018 ASCO/CAP recommendations.
Presenter: Carine Ngo
Session: Poster Display session 2
Resources:
Abstract
1096 - OncotypeDX® predictive nomogram for recurrence score output: a machine learning system based on quantitative immunochemistry analysis - ADAPTED01
Presenter: Fabio Marazzi
Session: Poster Display session 2
Resources:
Abstract
5426 - Geriatric parameters predict both disease-related and patient-reported outcomes in older patients with breast cancer
Presenter: Willeke van der Plas-Krijgsman
Session: Poster Display session 2
Resources:
Abstract
5865 - Patients with a 21-gene assay in South East London differ from the TAILORx trial population
Presenter: Charalampos Gousis
Session: Poster Display session 2
Resources:
Abstract
1312 - Predictive tools in adjuvant breast cancer – what is the standard of evidence supporting their utility? A literature review examining validation of Adjuvant!, Cancermath and NHS Predict
Presenter: Alice Loft
Session: Poster Display session 2
Resources:
Abstract
2445 - Oncologic outcome of invasive lobular carcinoma: Is it different from that of invasive ductal carcinoma?
Presenter: Hee Jun Choi
Session: Poster Display session 2
Resources:
Abstract
2476 - Pathologic response and survival efficacy in patients with initial nodal involvement after neoadjuvant chemotherapy in early breast cancer
Presenter: SERAFIN MORALES Murillo
Session: Poster Display session 2
Resources:
Abstract
3761 - Chemotherapy-induced amenorrhea: prognostic impact on premenopausal Egyptian patients with breast cancer
Presenter: Khaled Abdel Karim
Session: Poster Display session 2
Resources:
Abstract
4687 - Predicting the presence of breast cancer using circulating small RNA in the serum
Presenter: Yumiko Koi
Session: Poster Display session 2
Resources:
Abstract